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Background: Drug-eluting stents (DES) are better than bare-metal stents (BMS) in reducing restenosis. We determined if insurance influences the 
use of BMS or DES.
methods: We conducted a meta-analysis including all studies in PUBMED in which DES and BMS use were reported in Medicare and Medicaid, 
HMO insurance, commercial insurance and uninsured populations. We used the DerSimonian and Laird random-effects models to calculate the 
pooled relative risk (RR) of stent use according to insurance.
results: Our search strategy yielded 872 publications. We included 13 studies with 1,591,662 patients with Medicare or Medicaid, 260,530 
commercially insured patients and 145,403 patients with no insurance who received either BMS or DES. BMS were more frequently used in patients 
with government insurance. The RR of using BMS was 1.19; 95% CI, 1.14-1.25; p<0.01 for those with government insurance and the RR of BMS 
use was 1.40; 95% CI, 1.19-1.63; p<0.01 for those with no insurance when compared with commercial insurance. This same trend was seen when 
stratified by insurance types (Table).
conclusion: BMS are used more frequently in patients with government and no insurance, despite the proven clinical benefit of DES. Insurance 
status plays an important role in physicians’ decisions regarding stent usage.
Table: BMS vs. DES Use by Insurance Type
Type of insurance RR CI P-Value
Government vs. Commercial 1.19 1.14-1.25 0.01
Medicare vs. Commercial 1.11 1.03-1.21 0.01
Medicaid vs. Commercial 1.24 1.11-1.40 0.01
No insurance vs. Commercial 1.40 1.19-1.63 0.01
HMO vs. Commercial 1.05 1.00-1.09 0.06
